Cempra Pharmaceuticals


Baird Remains Bearish on Cempra Pharmaceuticals (CEMP); Believes Restrictions on Solithromycin Will Render Drug Commercially Unviable

Though the FDA’s Antimicrobial Drugs Advisory Committee voted in a 7-6 vote in favor of approval for Cempra Pharmaceuticals (NASDAQ:CEMP) pipeline drug solithromycin, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts